| Product Code: ETC13140002 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
Africa mRNA Vaccines and RNAi Therapeutics Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Africa mRNA Vaccines and RNAi Therapeutics Market Overview |
3.1 Africa Regional Macro Economic Indicators |
3.2 Africa mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Africa mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle |
3.4 Africa mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces |
3.5 Africa mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 Africa mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.7 Africa mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.8 Africa mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 Africa mRNA Vaccines and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Africa mRNA Vaccines and RNAi Therapeutics Market Trends |
6 Africa mRNA Vaccines and RNAi Therapeutics Market, 2021 - 2031 |
6.1 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021 - 2031 |
6.1.3 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Acute hepatic porphyria, 2021 - 2031 |
6.1.4 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Primary hyperoxaluria type 1, 2021 - 2031 |
6.1.5 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021 - 2031 |
6.2 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Administration, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By IV infusion, 2021 - 2031 |
6.2.3 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Subcutaneous, 2021 - 2031 |
6.3 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By End user, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Research Institutes, 2021 - 2031 |
6.3.3 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Hospitals and Clinics, 2021 - 2031 |
7 Africa mRNA Vaccines and RNAi Therapeutics Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.2.1 South Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.2.2 Egypt mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.2.3 Nigeria mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.2.4 Rest of Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Disease Type, 2021 - 2031 |
7.3 Africa mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
7.3.1 South Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Administration, 2021 - 2031 |
7.3.2 Egypt mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Administration, 2021 - 2031 |
7.3.3 Nigeria mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Administration, 2021 - 2031 |
7.3.4 Rest of Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By Administration, 2021 - 2031 |
7.4 Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By End user, 2021 - 2031 |
7.4.1 South Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By End user, 2021 - 2031 |
7.4.2 Egypt mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By End user, 2021 - 2031 |
7.4.3 Nigeria mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By End user, 2021 - 2031 |
7.4.4 Rest of Africa mRNA Vaccines and RNAi Therapeutics Market, Revenues & Volume, By End user, 2021 - 2031 |
8 Africa mRNA Vaccines and RNAi Therapeutics Market Key Performance Indicators |
9 Africa mRNA Vaccines and RNAi Therapeutics Market - Export/Import By Countries Assessment |
10 Africa mRNA Vaccines and RNAi Therapeutics Market - Opportunity Assessment |
10.1 Africa mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 Africa mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
10.3 Africa mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F |
10.4 Africa mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
11 Africa mRNA Vaccines and RNAi Therapeutics Market - Competitive Landscape |
11.1 Africa mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2022 |
11.2 Africa mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here